Brighter (DB:2HJ) - Stock Price, News & Analysis

This company listing is no longer active

This company may still be operating, however this listing is no longer active. Find out why through their latest events.

2HJ Stock Overview

Brighter AB (publ), a health-tech company, develops solutions for the treatment of chronic condition in Sweden and internationally.

About the company

2HJ fundamental analysis
Snowflake Score
Valuation	2/6
Future Growth	0/6
Past Performance	0/6
Financial Health	4/6
Dividends	0/6

Rewards

Risk Analysis

Has less than 1 year of cash runway

Highly volatile share price over the past 3 months

Shareholders have been substantially diluted in the past year

Earnings have declined by 42% per year over past 5 years

+ 2 more risks

Brighter AB (publ) Competitors

aap Implantate

XTRA:AAQ1

€8.0m

Audientes

DB:AUG

€6.9m

Geratherm Medical

XTRA:GME

€23.3m

elexxion

XTRA:E8X

€2.2m

Price History & Performance

Summary of all time highs, changes and price drops for Brighter
Historical stock prices
Current Share Price	€0.0001
52 Week High	€0.042
52 Week Low	€0.0001
Beta	1.62
1 Month Change	0%
3 Month Change	0%
1 Year Change	-99.76%
3 Year Change	-99.99%
5 Year Change	n/a
Change since IPO	-99.99%

Recent updates

Shareholder Returns

	2HJ	DE Medical Equipment	DE Market
7D	0%	-5.0%	-2.0%
1Y	-99.8%	-13.6%	-0.3%

Return vs Industry: 2HJ underperformed the German Medical Equipment industry which returned -20.7% over the past year.

Return vs Market: 2HJ underperformed the German Market which returned -16.6% over the past year.

Price Volatility

Is 2HJ's price volatile compared to industry and market?
2HJ volatility
2HJ Average Weekly Movement	1,761.6%
Medical Equipment Industry Average Movement	4.6%
Market Average Movement	4.8%
10% most volatile stocks in DE Market	10.0%
10% least volatile stocks in DE Market	2.4%

Stable Share Price: 2HJ's share price has been volatile over the past 3 months.

Volatility Over Time: 2HJ's weekly volatility has increased from 887% to 1762% over the past year.

About the Company

Founded	Employees	CEO	Website
2007	57	Erik Lissner	brighter.se

Brighter AB (publ), a health-tech company, develops solutions for the treatment of chronic condition in Sweden and internationally. It is developing Actiste, a daily diabetes care of insulin-treated diabetes; Actiste Mini for the treatment of non-insulin-treated diabetes; and Nectarine Health, an AI-based monitoring solution. The company offers its products to patients and their relatives, healthcare providers, authorities and governments, insurance companies and employers, pharmaceutical industry, clinical research organizations, and academic organizations.

Brighter AB (publ) Fundamentals Summary

How do Brighter's earnings and revenue compare to its market cap?
2HJ fundamental statistics
Market cap	€14.76m
Earnings (TTM)	-€16.94m
Revenue (TTM)	€3.05m

0.0x

P/S Ratio

0.0x

P/E Ratio

Is 2HJ overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
2HJ income statement (TTM)
Revenue	kr33.03m
Cost of Revenue	kr10.88m
Gross Profit	kr22.15m
Other Expenses	kr205.85m
Earnings	-kr183.70m

Last Reported Earnings

Jun 30, 2022

Next Earnings Date

Nov 29, 2022

Earnings per share (EPS)	-0.21
Gross Margin	67.05%
Net Profit Margin	-556.20%
Debt/Equity Ratio	1.7%

How did 2HJ perform over the long term?

See historical performance and comparison

This company listing is no longer active

2HJ Stock Overview

Rewards

Risk Analysis

Brighter AB (publ) Competitors

XTRA:AAQ1

€8.0m

DB:AUG

€6.9m

XTRA:GME

€23.3m

XTRA:E8X

€2.2m

Price History & Performance

Recent News & Updates

Nasdaq Stockholm AB Decides to Delist the Shares and Equity Rights of Brighter AB

Nasdaq Stockholm imposes a fine on Brighter AB (publ)

Brighter AB (Publ) Applies for Corporate Restructuring in Bid for Longer-Term Financing

Brighter AB (publ) Announces Executive Changes

Brighter AB (publ) to Report Fiscal Year 2022 Results on Apr 13, 2023

Second quarter 2022 earnings released: kr0.05 loss per share (vs kr0.21 loss in 2Q 2021)

Recent updates

Nasdaq Stockholm AB Decides to Delist the Shares and Equity Rights of Brighter AB

Nasdaq Stockholm imposes a fine on Brighter AB (publ)

Brighter AB (Publ) Applies for Corporate Restructuring in Bid for Longer-Term Financing

Brighter AB (publ) Announces Executive Changes

Brighter AB (publ) to Report Fiscal Year 2022 Results on Apr 13, 2023

Second quarter 2022 earnings released: kr0.05 loss per share (vs kr0.21 loss in 2Q 2021)

Brighter AB (Publ.) Announces its Actiste® Receives Telecommunication Type Approval in the United Arab Emirates

High number of new and inexperienced directors

Brighter AB (publ) Receives Final Approvals for Pilot Research with Insulin-Treated Diabetes Patients in the UAE

High number of new and inexperienced directors

Brighter's Interim CEO Erik Lissner Takes Permanent Role as the Company CEO

Brighter AB Announces Actiste®, for the First Time, Is Prescribed to A Patient Living with Diabetes in Qatar

700Brighter AB Announces Actiste, for the First Time, Is Prescribed to A Patient Living with Diabetes in Qatar

Brighter AB (Publ) Announces Appointment of Johnny Ludvigsson as Board Member

Brighter AB (publ) Announces First Patient Recruited for the Actiste Study in the United Kingdom

First quarter 2022 earnings released: kr0.07 loss per share (vs kr0.20 loss in 1Q 2021)

High number of new and inexperienced directors

Full year 2021 earnings released: kr0.60 loss per share (vs kr1.08 loss in FY 2020)

Brighter AB (Publ) Announces Launch and Commercial Availability of its Actiste® Service, Aiming to Improve the Quality of Life for People Living with Diabetes in Qatar

Full year 2021 earnings: EPS in line with analyst expectations despite revenue beat

Brighter AB (publ) to Report Fiscal Year 2021 Results on Apr 13, 2022

Brighter AB (publ) to Report Q3, 2022 Results on Nov 09, 2022

Brighter AB (publ), Annual General Meeting, May 05, 2022

Brighter AB (publ) has completed a Composite Units Offering in the amount of SEK 117.093404 million.

Brighter AB (publ) announces positive results for Actiste®

A shareholder of Blodtrycksdoktorn AB entered into an agreement to acquire an unknown stake in Blodtrycksdoktorn AB from Brighter AB (publ) (OM:BRIG) for SEK 5 million.

Beijing AddLife AB (publ) (OM:ALIF B) acquired Camanio AB from Brighter AB (publ) (OM:BRIG) for SEK 65 million.

Third quarter 2021 earnings released: kr0.20 loss per share (vs kr0.18 loss in 3Q 2020)

Brighter's Actiste Receives Final Outstanding Approval in Qatar

Interim Chief Financial Officer Julie Silber has left the company

Second quarter 2021 earnings released: kr0.20 loss per share (vs kr0.27 loss in 2Q 2020)

Brighter's Actiste Receives Telecommunication Approval in Qatar

Brighter's Actiste Mini Receives Telecommunication Approval in Qatar

Compatibility with New Insulins Opens Up New Market Opportunities for Brighter's Actiste

Brighter AB (Publ) Launches Innovative Pilot Project with Tomelilla Municipality

Brighter AB (Publ) Provides Revenue Guidance for the Year 2021

Brighter AB (Publ) Makes Progress with the User Experience Test of the Diabetes Management Solution Actiste

First quarter 2021 earnings released: kr0.20 loss per share (vs kr0.19 loss in 1Q 2020)

Brighter AB (Publ) Announces the Patent to Safely Combine MDD and IVDD Functionality into One Unit

Full year 2020 earnings released: kr1.04 loss per share (vs kr1.06 loss in FY 2019)

Brighter AB (publ) to Report Q4, 2021 Results on Feb 20, 2022

Brighter Signs 5-Year Distribution Agreement for Actiste in Qatar

Brighter AB (publ) Announces CEO Changes

Brighter AB (publ) Announces Diabetes Management Devices Actiste and Actiste Mini Receives Market Approval in Thailand

Brighter AB (publ) Announces Clarification of Information Regarding Agreements for Nigeria and Ghana

Brighter AB (publ) Signs 5-Year Agreement with Wssonlines Nigeria Ltd and Receives Initial Order for Actiste® Worth Eur 2.3 Million in Nigeria

Brighter AB (publ)'s Actiste® Mini Receives Market Approval in the Kingdom of Saudi Arabia

Brighter AB (Publ) Announces Nomination Committee for the AGM 2021

New 90-day high: €0.31

Brighter AB (publ) Announces Executive Changes

Brighter's Pioneering Diabetes Management Solution Actiste® Receives Market Approval in the United Arab Emirates

Third quarter 2020 earnings released: kr0.16 loss per share

Brighter AB (Publ) Announces Actiste Device and Its Associated Digital Platform Received Market Approval from the Saudi Food and Drug Authority

Founder & Executive Director recently sold €143.8k worth of stock

First half earnings released

First half earnings released

Brighter AB (publ) to Report Q4, 2020 Results on Feb 12, 2021

New 90-day low - €0.30